Research programme: serotonin 2 receptor antagonists - AnaMar

Drug Profile

Research programme: serotonin 2 receptor antagonists - AnaMar

Alternative Names: AM260; AM260 TASS; Am260, TASS; AMAP 312; AMAP332

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AnaMar Medical
  • Developer AcurePharma; AnaMar AB
  • Class Small molecules
  • Mechanism of Action Serotonin 2 receptor antagonists; Serotonin 2B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Inflammatory pain
  • Research Idiopathic pulmonary fibrosis
  • No development reported Osteoarthritis; Rheumatoid arthritis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammatory-pain in Sweden (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Osteoarthritis in Sweden (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in Sweden (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top